AGI-1067

DRUG2 trials

Sponsors

AtheroGenics

Conditions

AtherosclerosisCoronary Artery DiseaseDiabetesMyocardial InfarctionUnstable Angina

Phase 2

ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study

AtheroGenicsDiabetes

Start: 2007-08-31End: 2008-09-30Target: 1012Updated: 2008-02-06

Phase 3

ARISE - Aggressive Reduction of Inflammation Stops Events

AtheroGenicsAtherosclerosis, Coronary Artery Disease, Myocardial Infarction +1

Start: 2003-06-30End: 2006-12-31Target: 6000Updated: 2006-10-03

Related Papers

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.

2008-05-01152 citations